Team:USTC CHINA/Project/Overview

From 2013.igem.org

(Difference between revisions)
 
(29 intermediate revisions not shown)
Line 4: Line 4:
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" />
 +
<style type="text/css">
 +
</style>
</head>
</head>
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png">
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png">
Line 10: Line 12:
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div>
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div>
-
    <ul id="nav">
+
<ul id="nav">
         <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li>
         <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li>
         <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a>
         <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a>
             <ul class="subs">
             <ul class="subs">
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li>
-
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></li>
+
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li>
-
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Parts">Parts</a></li>
+
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></li>
             </ul>
             </ul>
         </li>
         </li>
Line 28: Line 31:
         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a>
         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a>
               <ul class="subs">
               <ul class="subs">
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/ReporterSystem">Kill Switch</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/KillSwitch">Kill Switch</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/MiceModeling">Designs Of Immune Experiments</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/DesignsofImmuneExperiments">Designs of Immune Experiments</a></li>
               </ul>
               </ul>
         </li>
         </li>
Line 43: Line 46:
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li>
                   <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li>
                   <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/Attribution">Attribution</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Attributions">Attributions</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/JudgingForm">Judging Form</a></li>
+
                   <li><a href="https://igem.org/2013_Judging_Form?id=1074#iGEM_Medals">Achievements</a></li>
               </ul>
               </ul>
         </li>
         </li>
Line 61: Line 64:
         <div id="overview-bar" class="basic-bar">
         <div id="overview-bar" class="basic-bar">
         <h1>Overview</h1>
         <h1>Overview</h1>
-
         <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
+
         <p align="justify">In our world, billions of people are suffering from contagions while only parts of contagions can be effectively prevented by existing vaccines. The disadvantages of traditional vaccines, like  being produced and purified with strict requirements on temperature, have limited their application, especially in developing countries. </p>
-
<img src="https://static.igem.org/mediawiki/igem.org/e/ec/2013ustc-china_traditional_vaccine_transport.jpg" width="400" height="300" />
+
<div align="center"><img src="https://static.igem.org/mediawiki/igem.org/e/ec/2013ustc-china_traditional_vaccine_transport.jpg" width="400" height="300" />
-
<div class="atfigure" align="center" style="width:400px;">Fig1. hard shipping in some area </div>
+
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig1. Difficult shipping in remote areas </div></div>
-
<p>This year, our project focused on a revolutionary vaccine delivery. We chose bacillus subtilis as chassis to establish a transdermal vaccine fresh secreting band-aid which consists of four engineering b.subtilis, each of them carries a gene circuit independently.</p>
+
<p align="justify">This year, our project focused on a revolutionary vaccine delivery. We bring a fresh Medication into the world, which contains an in situ expression system, and our product is a biological transdermal vaccine patch called T-vaccine. We chose <i>Bacillus subtilis</i> as chassis to establish the band-aid secreting fresh vaccines. The new vaccine consists of four engineering <i>B.subtilis</i>, each of which carried a gene circuit independently.</p>
-
<img src="https://static.igem.org/mediawiki/2013/archive/e/ed/20130923171924!2013igemustc_Standardization.png" width="400" height="350" />
+
<div align="center"><img src="https://static.igem.org/mediawiki/2013/archive/e/ed/20130923171924!2013igemustc_Standardization.png" width="400" height="350" />
-
<div class="atfigure" align="center" style="width:400px;">Fig2. block-based design </div>
+
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig2. block-based design </div></div>
-
<p>By using an excellent transdermal peptide TD1, three of them could express a serious of fusion proteins(antigen, 2 kinds of adjuvants) which could penetrating the skin and work as traditional vaccine molecule.The fourth type of them is our “reporter” which could notify users whether the band-aid works well and when they could stick or tear off the patch. Moreover we designed a reliable suicide system in bacillus subtilis for the very first time in iGEM. So it would be OK if our users tear patches off and throw them away. Cheap and convenient, we just create a world without needle. </p>   
+
<p align="justify">With an excellent transdermal peptide TD1, three of the engineering <i>B.subtilis</i> could express a series of fusion proteins (the antigen and two kinds of adjuvants), which could penetrate the skin and work as traditional vaccine molecules. The fourth bacteria are our "reporter" ,which would notify users whether the band-aid works well and when the patch can be pasted . Moreover, we designed a reliable suicide system in <i>B.subtilis</i> to ensure biosafety.</p>
 +
<div align="center"><img src="https://static.igem.org/mediawiki/2013/9/91/2013ustc-china_Needles.png" width="400" height="350" />
 +
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig3. No Needle </div></div>
 +
<p align="justify">T-vaccine can be stored from minus 20 to 60 Celsius, which grants its great advantage transportation and enables us to reach every remote corner of the world to help eliminate contagions from our world. It is also proved that transdermal vaccine is an effective method for a variety of pathogens such as: tuberculosis, anthrax, hepatitis B and so on. Additionally, we have created a world free from needles. Consider these advantages, T-vaccine is expected to set up a  promising vaccine research and a new development orientation.</p>   
</div>
</div>
</div>
</div>
Line 74: Line 80:
<div class="clear"></div>
<div class="clear"></div>
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div>
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div>
-
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></div>
+
 
-
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">Background</a></div>
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></div>
-
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">Design</a></div>
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></div>
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div>
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div>
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div>
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div>
-
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">Furthur Work</a></div>
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/AdvancingWork">Advancing Work</a></div>
-
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Parts">Parts</a></div>
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work</a></div>
 +
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div>
</div></div></div>         
</div></div></div>         
          
          
</body>
</body>
</html>
</html>

Latest revision as of 12:24, 28 October 2013

Overview

In our world, billions of people are suffering from contagions while only parts of contagions can be effectively prevented by existing vaccines. The disadvantages of traditional vaccines, like being produced and purified with strict requirements on temperature, have limited their application, especially in developing countries.

Fig1. Difficult shipping in remote areas

This year, our project focused on a revolutionary vaccine delivery. We bring a fresh Medication into the world, which contains an in situ expression system, and our product is a biological transdermal vaccine patch called T-vaccine. We chose Bacillus subtilis as chassis to establish the band-aid secreting fresh vaccines. The new vaccine consists of four engineering B.subtilis, each of which carried a gene circuit independently.

Fig2. block-based design

With an excellent transdermal peptide TD1, three of the engineering B.subtilis could express a series of fusion proteins (the antigen and two kinds of adjuvants), which could penetrate the skin and work as traditional vaccine molecules. The fourth bacteria are our "reporter" ,which would notify users whether the band-aid works well and when the patch can be pasted . Moreover, we designed a reliable suicide system in B.subtilis to ensure biosafety.

Fig3. No Needle

T-vaccine can be stored from minus 20 to 60 Celsius, which grants its great advantage transportation and enables us to reach every remote corner of the world to help eliminate contagions from our world. It is also proved that transdermal vaccine is an effective method for a variety of pathogens such as: tuberculosis, anthrax, hepatitis B and so on. Additionally, we have created a world free from needles. Consider these advantages, T-vaccine is expected to set up a promising vaccine research and a new development orientation.